Advertisement

Topics

MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

19:00 EDT 8 Aug 2017 | Net Resources International

MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6).

Original Article: MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C

NEXT ARTICLE

More From BioPortfolio on "MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...